ReviewAesthetic surgery journal2017
The Practical Use of AbobotulinumtoxinA in Aesthetics.
Review in Aesthetic surgery journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial.Aesthetic plastic surgery · 2025Trial
- Findings From the Great British and Northern Ireland Botulinum Toxin Survey: Treatment Outcomes, Patient Experience, and Regulations From a Cross-Sectional Survey.Aesthetic surgery journal. Open forum · 2025Article
- [New botulinum toxins for aesthetic dermatology : A comprehensive review].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II.Journal of cosmetic dermatology · 2020Review
- Botulinum neurotoxin formulations: overcoming the confusion.Clinical, cosmetic and investigational dermatology · 2018Review
- Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport).Aesthetic surgery journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin (BoNT) has been approved for aesthetic use since 2002. Since then, clinical studies and expert use have informed our understanding of how BoNT exerts its clinical effect and the practical use of this product across a number of aesthetic applications. This review discusses the clinical properties and characteristics of abobotulinumtoxinA, which patients are suitable for its use, and how it can be utilized to treat facial rhytides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.